You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Preclinical assessment of the GluN2B inhibitor clinical candidate NP10679 as a medication to prevent opiate abuse relapse
SBC: NEUROP, INC. Topic: NIDAAbstract The current status of opiate abuse in the US has been characterized as arapidly evolving publichealth crisisrequiring the need for new treatments to address the problemPersistent relapse toaddictive drug use is a significant challenge to addiction therapyMedications targeting theneurobiology underlying relapse offer additional avenues for treatmentGlutamate signaling iscritically involved ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Software and services to advance dose-response modeling in chemical risk assesment
SBC: KS & ASSOCIATES LLC Topic: NCATSPROJECT SUMMARY Chemical risk assessment has been widely applied in chemical industry as a necessary step to get new commercial chemicals registeredand in governmental agencies as a critical procedure to evaluate the toxicity of chemicals in order to properly regulate them to protect human health and the environmentThe Lautenberg Chemical Safety Act further strengthens the importance of chemical r ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A New Small-Molecule Kinase Inhibitor for Breast Cancer
SBC: NuPeak Therapeutics, Inc. Topic: 102NuPeak Therapeutics Incis a biotechnology start up companyC corporationdesigned to deliver a first inclass small molecule kinase inhibitorThe present Project is aimed at an inhibitor for treatment of breast cancerwhich remains a leading cause of morbidity and mortality in the U Sdespite current therapeutic approachesIn that contextwe identified a novel typeimmune response that activates mitogen ac ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Glycoengineering a bioconjugate vaccine against Klebsiella pneumoniae
SBC: VaxNewMO Topic: NIAIDPROJECT SUMMARY Klebsiella pneumoniae is an increasingly prevalent drug resistant nosocomial pathogenCommonlyKpneumoniae isolates are carbapenem resistantwhich are referred to as carbapenem resistant EnterobacteriaceaeCREand present significantly less therapeutic intervention optionsFurthermorecommunity acquired infections associated with hypervirulent isolates of Kpneumoniae have emerged that are ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Chronic intrapulmonary delivery of a novel small molecule Wnt/beta-catenin inhibitor for Idiopathic Pulmonary Fibrosis
SBC: BETA CAT PHARMACEUTICALS, INC. Topic: NHLBIProject Summary Idiopathic pulmonary fibrosisIPFis a devastatingprogressive disease with no known cure and no treatment that convincingly alters the disease course or significantly improves mortalityThe objective of this proposal is the development of nebulized delivery of the small molecule inhibitor of Wntcatenin signalingBCfor Idiopathic Pulmonary FibrosisPre clinical studies in rodentsdogsand ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Develop novel lutein biomanufacturing in a nonmodel yeast via engineered metabolons and metabolic analyses
SBC: Arch Innotek, LLC Topic: 300Project Summary Arch Innotek proposes to develop a sustainablecost effective fermentation process to produce lutein using engineered yeastLutein is an important antioxidant compound that can slow the progression of vision loss caused by age related macular degenerationAMDcataractsand retinitis pigmentosaAside from protecting eyesdietary intake of lutein can reduce risk of skin disordersseveral typ ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Catheter Development for Epicardial Atrial Gene Painting
SBC: RITHIM BIOLOGICS INC. Topic: NCATSABSTRACT Atrial fibrillationAFis the most common rhythm disturbance in the US and other developed countriesAF significantly affects the lives of the afflictedcausing symptoms that range from palpitations to fatigueweakness and activity intoleranceand substantially increasing the risks of strokecongestive heart failure and deathThe impact on public health is substantialwith more thanhospital admiss ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
MRI-compatible and integrated devices for simultaneous neural recording, stimulation, imaging
SBC: MR-LINK LLC Topic: 101Project Summary The use of technologies for imagingrecording and modulating brain activity is rapidly advancing neuroscienceNotablymicroelectrodes are used to locally record neural activity or to perturb circuit functionFunctional magnetic resonance imagingfMRIis widely used to image large scale patterns of hemodynamic fluctuations accompanying neural activityAlthough these techniques have become ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Quantitative Handwriting Assessment Tool for Healthy and Impaired Children
SBC: NEWVENTUREIQ LLC Topic: NICHDNo technology currently exists for objective assessment of handwritingeven though overmillion individuals in the United States suffer from disorders that affect handwritingincludingmillion children with dyspraxia and overolder adults with Parkinsonandapos s diseaseThis lack of assessment technology creates a barrier to effective carebecause occupational therapists cannot easily distinguish motor d ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Mitigation of Acute and Chronic Kidney Injuries by Systemic Infusion of Adipose-Derived Soluble Therapeutic Factor Concentrate
SBC: NeuroFx, Inc. Topic: 300ABSTRACT Acute kidney injuryAKIis a syndrome characterized by rapid loss of the kidneyandapos s excretory functionAKI is the leading cause of nephrology consultation and results inmillion hospital admissions a yearThe socioeconomic impact of AKI is significantresulting in $billion cost to the health care systemDespite the high rate of incidence of AKIno therapy currently existsother than supportiv ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health